Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

Knox, S J

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Feb 2000 - 406-14 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

1078-0432


Adult
Aged
Anemia--etiology
Antibodies, Monoclonal--adverse effects
Biotin--administration & dosage
Colonic Neoplasms--pathology
Female
Humans
Leukopenia--etiology
Male
Middle Aged
Neoplasm Metastasis
Organometallic Compounds--administration & dosage
Radioimmunotherapy
Radiopharmaceuticals--adverse effects
Thrombocytopenia--etiology
Yttrium Radioisotopes--adverse effects